Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Therapeutic options for patients with primary refractory/early relapsed DLBCL

Manali Kamdar, MD, University of Colorado, Aurora, CO, gives an overview of treatment options available for patients with primary refractory and early relapsed diffuse large B-cell lymphoma (DLBCL), highlighting promising findings obtained from clinical trials. Dr Kamdar first discusses the need to look beyond autologous stem cell transplantation (autoSCT) in these patients, and further notes the value of CAR-T therapy and moving these agents into earlier lines. Following this, Dr Kamdar discusses findings from several pivotal trials, including ZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), and PILOT (NCT03483103), and concludes by highlighting treatment options for patients ineligible for CAR-T therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.